BioPorto A/S announced changes to the Executive Management. By mutual agreement, BioPorto?s CEO, Anthony Pare, is stepping down and leaving BioPorto with effect from January 9, 2024. Peter Mørch Eriksen has been appointed as interim CEO.

The Board of Directors has as of January 9, 2024 appointed Board Member Peter Mørch Eriksen as interim CEO of the Company. Peter Mørch Eriksen will remain in his position as Board Member at least until the expiry of his election period at this year?s Annual General Meeting. Peter Mørch Eriksen has spent more than 25 years in the MedTech/life science industries, including as CEO of Sense A/S and VP of Medtronic.

Peter has previously been the CEO of BioPorto in the period from 2013 ? 2021 and has served as a Board Member in BioPorto since then. Further, Peter is the Chairman of FluoGuide A/S and MONSENSO A/S. Together with the Board of Directors and the BioPorto team, Peter will finalize work that has already been commenced on the Company?s plans for commercialization, FDA instrument- & indication expansion, financial guidance for 2024 and capital requirements which is to be published by mid-February 2024.